Advisornet Financial’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $256K | Buy |
152,122
+10,065
| +7% | +$14.6K | 0.01% | 575 |
|
|
2026
Q1 | $188K | Buy |
142,057
+8,290
| +6% | +$14.8K | 0.01% | 630 |
|
|
2025
Q4 | $250K | Buy |
133,767
+7,950
| +6% | +$15.3K | 0.01% | 549 |
|
|
2025
Q3 | $161K | Buy |
125,817
+17,048
| +16% | +$23.1K | 0.01% | 654 |
|
|
2025
Q2 | $135K | Buy |
108,769
+32,105
| +42% | +$37.1K | 0.01% | 672 |
|
|
2025
Q1 | $90.5K | Buy |
76,664
+11,895
| +18% | +$18.2K | 0.01% | 757 |
|
|
2024
Q4 | $119K | Buy |
64,769
+4,563
| +8% | +$8.91K | 0.01% | 634 |
|
|
2024
Q3 | $102K | Buy |
60,206
+16,888
| +39% | +$27.7K | 0.01% | 695 |
|
|
2024
Q2 | $59.3K | Buy |
43,318
+6,473
| +18% | +$13.1K | 0.01% | 768 |
|
|
2024
Q1 | $138K | Buy |
36,845
+1,325
| +4% | +$7.76K | 0.01% | 548 |
|
|
2023
Q4 | $348K | Buy |
35,520
+6,577
| +23% | +$53.8K | 0.03% | 378 |
|
|
2023
Q3 | $242K | Buy |
28,943
+34
| +0.1% | +$389 | 0.02% | 416 |
|
|
2023
Q2 | $384K | Buy |
28,909
+197
| +0.7% | +$2.39K | 0.03% | 354 |
|
|
2023
Q1 | $332K | Buy |
28,712
+125
| +0.4% | +$1.24K | 0.03% | 364 |
|
|
2022
Q4 | $234K | Buy |
28,587
+525
| +2% | +$4.52K | 0.02% | 443 |
|
|
2022
Q3 | $163K | Hold |
28,062
| – | – | 0.02% | 547 |
|
|
2022
Q2 | $124K | Buy |
28,062
+1,390
| +5% | +$8.45K | 0.01% | 612 |
|
|
2022
Q1 | $243K | Hold |
26,672
| – | – | 0.02% | 512 |
|
|
2021
Q4 | $546K | Sell |
26,672
-1,180
| -4% | -$28.5K | 0.03% | 385 |
|
|
2021
Q3 | $712K | Sell |
27,852
-700
| -2% | -$20.7K | 0.05% | 301 |
|
|
2021
Q2 | $998K | Sell |
28,552
-490
| -2% | -$14.3K | 0.07% | 253 |
|
|
2021
Q1 | $967K | Sell |
29,042
-4,573
| -14% | -$160K | 0.07% | 246 |
|
|
2020
Q4 | $872K | Sell |
33,615
-16,405
| -33% | -$279K | 0.07% | 240 |
|
|
2020
Q3 | $494K | Sell |
50,020
-7,930
| -14% | -$45.7K | 0.04% | 338 |
|
|
2020
Q2 | $200K | Buy |
57,950
+19,000
| +49% | +$64.7K | 0.02% | 496 |
|
|
2020
Q1 | $119K | Buy |
38,950
+2,500
| +7% | +$10.2K | 0.01% | 572 |
|
|
2019
Q4 | $187K | Hold |
36,450
| – | – | 0.02% | 517 |
|
|
2019
Q3 | $188K | Buy |
36,450
+5,500
| +18% | +$30.8K | 0.02% | 526 |
|
|
2019
Q2 | $187K | Buy |
30,950
+10,550
| +52% | +$74K | 0.02% | 462 |
|
|
2019
Q1 | $147K | Hold |
20,400
| – | – | 0.02% | 475 |
|
|
2018
Q4 | $151K | Hold |
20,400
| – | – | 0.02% | 438 |
|
|
2018
Q3 | $110K | Hold |
20,400
| – | – | 0.01% | 535 |
|
|
2018
Q2 | $72K | Buy |
20,400
+7,800
| +62% | +$21.6K | 0.01% | 610 |
|
|
2018
Q1 | $26K | Buy |
12,600
+10,000
| +385% | +$26K | ﹤0.01% | 871 |
|
|
2017
Q4 | $7K | Buy |
+2,600
| New | +$9.1K | ﹤0.01% | 1070 |
|
Other funds holding PACB
AIM
NAMA
Advisornet Financial's PACB Position: Q2 2026 in Review
Advisornet Financial increased its Pacific Biosciences (PACB) stake by 7.1% in Q2 2026, buying an estimated $14.6K and bringing the position to 152,122 shares worth $256K. The position accounts for 0.01% of the portfolio, ranked #575.
Advisornet Financial first reported a position in PACB in Q4 2017 and has held it in 35 quarters since. The position peaked at $998K in Q2 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.
- Advisornet Financial held 152,122 shares of Pacific Biosciences worth $256K as of Q2 2026.
- Advisornet Financial bought 10,065 Pacific Biosciences shares in Q2 2026, an estimated $14.6K.
- Pacific Biosciences made up 0.01% of Advisornet Financial's portfolio in Q2 2026, its #575 holding.
- Advisornet Financial first reported a position in Pacific Biosciences in Q4 2017 and has held it in 35 quarters since.
- Advisornet Financial's Pacific Biosciences position peaked at $998K in Q2 2021.
- 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.
Based on Advisornet Financial's 13F filing for Q2 2026, filed 23 Jul 2026.